Skip to main content
Erschienen in: International Journal of Colorectal Disease 8/2013

01.08.2013 | Review

Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis

verfasst von: Yu-Yu Lu, Jin-Hua Chen, Chun-Ru Chien, William Tzu-Liang Chen, Shih-Chuan Tsai, Wan-Yu Lin, Chia-Hung Kao

Erschienen in: International Journal of Colorectal Disease | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Aim

The purpose of the present study was to conduct a systematic review and meta-analysis of the published literature to assess the diagnostic performance of FDG-PET or PET/CT in the detection of recurrent colorectal cancer (CRC) rising in patients with elevated CEA.

Materials and methods

The authors conducted a systematic MEDLINE search of published articles. Two reviewers independently assessed the methodological quality of each study. We estimated pooled sensitivity and specificity and positive and negative likelihood ratios, and summary receiver-operating characteristic curves in the detection of recurrent CRC in patients with elevated CEA.

Results

Eleven studies with a total of 510 patients met the inclusion criteria. One hundred and six patients (106/510 = 20.8 %) had true-negative FDG-PET (PET/CT) results in detection of recurrent CRC when rising CEA. The pooled estimates of sensitivity and specificity and positive and negative likelihood ratios of FDG-PET in the detection of tumor recurrence in CRC patients with elevated CEA were 90.3 % (95 % CI, 85.5–94.0 %), 80.0 % (95 % CI, 67.0–89.6 %), 2.88 (95 % CI, 1.37–6.07), and 0.12 (95 % CI, 0.07–0.20), respectively. The pooled estimates of sensitivity and specificity and positive and negative likelihood ratios of FDG-PET/CT in the detection of tumor recurrence in CRC patients with elevated CEA were 94.1 % (95 % CI, 89.4–97.1 %), 77.2 % (95 % CI, 66.4–85.9 %), 4.70 (95 % CI, 0.82–12.13), and 0.06 (95 % CI, 0.03–0.13), respectively.

Conclusions

Whole-body FDG-PET and PET/CT are valuable imaging tools for the assessment of patients with suspected CRC tumor recurrence based on the increase of CEA.
Literatur
1.
Zurück zum Zitat Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRef Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRef
2.
Zurück zum Zitat Goldberg RM (2006) Intensive surveillance after stage II or III colorectal cancer: is it worth it? J Clin Oncol 24:330–331PubMedCrossRef Goldberg RM (2006) Intensive surveillance after stage II or III colorectal cancer: is it worth it? J Clin Oncol 24:330–331PubMedCrossRef
3.
4.
Zurück zum Zitat Obrand DI, Gordon PH (1997) Incidence and patterns of recurrence following curative resection of colon cancer. Dis Colon Rectum 40:15–24PubMedCrossRef Obrand DI, Gordon PH (1997) Incidence and patterns of recurrence following curative resection of colon cancer. Dis Colon Rectum 40:15–24PubMedCrossRef
5.
Zurück zum Zitat Vernava AM III, Longo WE, Virgo KS et al (1994) Current follow-up strategies after resection of colon cancer. Results of a survey of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 37:573–583PubMedCrossRef Vernava AM III, Longo WE, Virgo KS et al (1994) Current follow-up strategies after resection of colon cancer. Results of a survey of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 37:573–583PubMedCrossRef
6.
Zurück zum Zitat Carriquiry LA, Pineyro A (1999) Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 42:921–929PubMedCrossRef Carriquiry LA, Pineyro A (1999) Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 42:921–929PubMedCrossRef
7.
Zurück zum Zitat Mitchell EP (1998) Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin Oncol 25:12–20PubMed Mitchell EP (1998) Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin Oncol 25:12–20PubMed
8.
Zurück zum Zitat Moss AA (1989) Imaging of colorectal carcinoma. Radiology 170:308–310PubMed Moss AA (1989) Imaging of colorectal carcinoma. Radiology 170:308–310PubMed
9.
Zurück zum Zitat Tempero M, Brand R, Holdeman K et al (1995) New imaging techniques in colorectal cancer. Semin Oncol 22:448–471PubMed Tempero M, Brand R, Holdeman K et al (1995) New imaging techniques in colorectal cancer. Semin Oncol 22:448–471PubMed
10.
Zurück zum Zitat Ruhlmann J, Schomburg A, Bender H et al (1997) Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 40:1195–1204PubMedCrossRef Ruhlmann J, Schomburg A, Bender H et al (1997) Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 40:1195–1204PubMedCrossRef
11.
Zurück zum Zitat Flanagan FL, Dehdashti F, Ogunbiyi OA et al (1998) Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 227:319–323PubMedCrossRef Flanagan FL, Dehdashti F, Ogunbiyi OA et al (1998) Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 227:319–323PubMedCrossRef
12.
Zurück zum Zitat Flamen P, Stroobants S, Van Cutsem E et al (1999) Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d glucose in recurrent colorectal cancer. J Clin Oncol 17:894–901PubMed Flamen P, Stroobants S, Van Cutsem E et al (1999) Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d glucose in recurrent colorectal cancer. J Clin Oncol 17:894–901PubMed
13.
Zurück zum Zitat Zervos EE, Badgwell BD, Burak WE Jr et al (2001) Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 130:636–643PubMedCrossRef Zervos EE, Badgwell BD, Burak WE Jr et al (2001) Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 130:636–643PubMedCrossRef
14.
Zurück zum Zitat Simo M, Lomena F, Setoain J et al (2002) FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun 23:975–982PubMedCrossRef Simo M, Lomena F, Setoain J et al (2002) FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun 23:975–982PubMedCrossRef
15.
Zurück zum Zitat Liu FY, Chen JS, Changchien CR et al (2005) Utility of 2-fluoro-2-deoxy-d-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum 48:1900–1912PubMedCrossRef Liu FY, Chen JS, Changchien CR et al (2005) Utility of 2-fluoro-2-deoxy-d-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum 48:1900–1912PubMedCrossRef
16.
Zurück zum Zitat Maldonado A, Sancho F, Cerdan J et al (2000) FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level: experience in 72 patients. Clin Positron Imaging 3:170PubMedCrossRef Maldonado A, Sancho F, Cerdan J et al (2000) FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA level: experience in 72 patients. Clin Positron Imaging 3:170PubMedCrossRef
17.
Zurück zum Zitat Kalff V, Hicks RJ, Ware RE et al (2002) The clinical impact of (18)F-FDG-PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 43:492–499PubMed Kalff V, Hicks RJ, Ware RE et al (2002) The clinical impact of (18)F-FDG-PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 43:492–499PubMed
18.
Zurück zum Zitat Chen LB, Tong JL, Song HZ et al (2007) (18)FDG-PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 13:5025–5029PubMed Chen LB, Tong JL, Song HZ et al (2007) (18)FDG-PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 13:5025–5029PubMed
19.
Zurück zum Zitat Chen YK, Yeh CL, Tsui CC et al (2011) F-18 FDG-PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med 36:553–559PubMedCrossRef Chen YK, Yeh CL, Tsui CC et al (2011) F-18 FDG-PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med 36:553–559PubMedCrossRef
20.
Zurück zum Zitat Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12:1293–1316PubMedCrossRef Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12:1293–1316PubMedCrossRef
21.
Zurück zum Zitat Zamora J, Abraira V, Muriel A et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31PubMedCrossRef Zamora J, Abraira V, Muriel A et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31PubMedCrossRef
22.
Zurück zum Zitat Imdahl A, Reinhardt MJ, Nitzsche EU et al (2000) Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 385:129–134PubMedCrossRef Imdahl A, Reinhardt MJ, Nitzsche EU et al (2000) Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 385:129–134PubMedCrossRef
23.
Zurück zum Zitat Staib L, Schirrmeister H, Reske SN et al (2000) Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 180:1–5PubMedCrossRef Staib L, Schirrmeister H, Reske SN et al (2000) Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 180:1–5PubMedCrossRef
24.
Zurück zum Zitat Hung GU, Shiau YC, Tsai SC et al (2001) Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 21:1375–1378PubMed Hung GU, Shiau YC, Tsai SC et al (2001) Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 21:1375–1378PubMed
25.
Zurück zum Zitat Imbriaco M, Akhurst T, Hilton S et al (2000) Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clin Positron Imaging 3:107–114PubMedCrossRef Imbriaco M, Akhurst T, Hilton S et al (2000) Whole-body FDG-PET in patients with recurrent colorectal carcinoma. A comparative study with CT. Clin Positron Imaging 3:107–114PubMedCrossRef
26.
Zurück zum Zitat Choi MY, Lee KM, Chung JK et al (2005) Correlation between serum CEA level and metabolic volume as determined by FDG-PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med 19:123–129PubMedCrossRef Choi MY, Lee KM, Chung JK et al (2005) Correlation between serum CEA level and metabolic volume as determined by FDG-PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med 19:123–129PubMedCrossRef
27.
Zurück zum Zitat Lee JH, Park SG, Jee KN et al (2010) Performance of FDG-PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Nucl Med Commun 31:576–582PubMed Lee JH, Park SG, Jee KN et al (2010) Performance of FDG-PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Nucl Med Commun 31:576–582PubMed
28.
Zurück zum Zitat Sarikaya I, Bloomston M, Povoski SP et al (2007) FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 5:64–71PubMedCrossRef Sarikaya I, Bloomston M, Povoski SP et al (2007) FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 5:64–71PubMedCrossRef
29.
Zurück zum Zitat Flamen P, Hoekstra OS, Homans F et al (2001) Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 37:862–869PubMedCrossRef Flamen P, Hoekstra OS, Homans F et al (2001) Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 37:862–869PubMedCrossRef
30.
Zurück zum Zitat Libutti SK, Alexander HR Jr, Choyke P et al (2001) A prospective study of 2-[18F] fluoro-2-deoxy-d-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 8:779–786PubMedCrossRef Libutti SK, Alexander HR Jr, Choyke P et al (2001) A prospective study of 2-[18F] fluoro-2-deoxy-d-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 8:779–786PubMedCrossRef
31.
Zurück zum Zitat Shen YY, Liang JA, Chen YK et al (2006) Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology 53:348–350PubMed Shen YY, Liang JA, Chen YK et al (2006) Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. Hepatogastroenterology 53:348–350PubMed
32.
Zurück zum Zitat Kyoto Y, Momose M, Kondo C et al (2010) Ability of 18F-FDG-PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. Ann Nucl Med 24:395–401PubMedCrossRef Kyoto Y, Momose M, Kondo C et al (2010) Ability of 18F-FDG-PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. Ann Nucl Med 24:395–401PubMedCrossRef
33.
Zurück zum Zitat Metser U, You J, McSweeney S et al (2010) Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG-PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol 194:766–771PubMedCrossRef Metser U, You J, McSweeney S et al (2010) Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG-PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol 194:766–771PubMedCrossRef
34.
Zurück zum Zitat Mittal BR, Senthil R, Kashyap R et al (2011) 18F-FDG-PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun 32:789–793PubMedCrossRef Mittal BR, Senthil R, Kashyap R et al (2011) 18F-FDG-PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nucl Med Commun 32:789–793PubMedCrossRef
35.
Zurück zum Zitat Ozkan E, Soydal C, Araz M et al (2012) The role of 18F-FDG-PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Nucl Med Commun 33:395–402PubMedCrossRef Ozkan E, Soydal C, Araz M et al (2012) The role of 18F-FDG-PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Nucl Med Commun 33:395–402PubMedCrossRef
36.
Zurück zum Zitat Sanli Y, Kuyumcu S, Ozkan ZG, et al. (2012) The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med 26:551–558 Sanli Y, Kuyumcu S, Ozkan ZG, et al. (2012) The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med 26:551–558
Metadaten
Titel
Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis
verfasst von
Yu-Yu Lu
Jin-Hua Chen
Chun-Ru Chien
William Tzu-Liang Chen
Shih-Chuan Tsai
Wan-Yu Lin
Chia-Hung Kao
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 8/2013
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-013-1659-z

Weitere Artikel der Ausgabe 8/2013

International Journal of Colorectal Disease 8/2013 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.